摘要
背景:为实体器官移植受者提供的长期免疫抑制治疗不可避免地导致显着抑制免疫防御;这导致频繁的皮肤感染和恶性肿瘤,这是移植患者的发病率和死亡率的重要原因。与一般人群相比,实体器官移植受者皮肤癌的发病率和风险升高,基底细胞癌风险增加10倍,鳞状细胞癌风险增加50-100倍。免疫抑制药物的时间表影响皮肤恶性肿瘤的类型和时间,但内源性和外源性危险因素也起到关键作用。 方法和结果:在这里,我们将回顾表皮癌化学预防的最新进展,以便为参与移植受者管理的临床医生提供有用的信息。包括在同行评议的期刊上发表的一百一十四篇论文。 结论:化学预防将是控制高危患者皮肤癌变的关键。
关键词: 化学预防,皮肤癌,实体器官移植,免疫抑制,烟酰胺,维甲酸。
Current Medicinal Chemistry
Title:Chemoprevention of Skin Carcinomas in High-Risk Transplant Recipients
Volume: 25 Issue: 6
关键词: 化学预防,皮肤癌,实体器官移植,免疫抑制,烟酰胺,维甲酸。
摘要: Background: Long-term immunosuppressive therapy, as provided to solid organ transplant recipients, inevitably results in a significant inhibition of immune defenses; this leads to frequent skin infections and malignancies, which represent an important cause of morbidity and mortality for transplanted patients. The incidence and risk of skin carcinomas are elevated in solid organ transplant recipients in comparison with the general population, with a 10-fold increased risk for basal cell carcinoma and a 50-100-fold for squamous cell carcinoma. The schedule of immunosuppressive drugs influences the type and timing of skin malignancies, but a crucial role is also played by endogenous and exogenous risk factors.
Methods & Results: Here, we will review the state-of-the-art in chemoprevention of epidermal carcinomas in order to provide useful information for clinicians involved in the management of transplant recipients. One-hundred and forteen paper, published on peerreviewed journals, has been included.
Conclusion: Chemoprevention would be key in controlling skin carcinogenesis in high-risk patients.
Export Options
About this article
Cite this article as:
Chemoprevention of Skin Carcinomas in High-Risk Transplant Recipients, Current Medicinal Chemistry 2018; 25 (6) . https://dx.doi.org/10.2174/0929867324666171003123056
DOI https://dx.doi.org/10.2174/0929867324666171003123056 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Cell Migration and Invasion by Specific Modules of uPA: Mechanistic Insights and Specific Inhibitors
Current Drug Targets Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets Metabolite Quantification in Tumours by Magnetic Resonance Spectroscopy: Objectives, Results and Perspectives
Current Medical Imaging Radiolabelled Quinoline Derivaties for the PET Imaging of Peripheral Benzodiazepine Receptor
Current Medical Imaging Prevalence of Vertebral Fractures, Vascular Calcifications, and Mortality in Warfarin Treated Hemodialysis Patients
Current Vascular Pharmacology Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Drugs Interfering with Apoptosis in Breast Cancer
Current Pharmaceutical Design The Promise of Plant Polyphenols as the Golden Standard Skin Anti-Inflammatory Agents
Current Drug Metabolism Phenolic Compounds in Prevention and Treatment of Skin Cancers: A Review
Current Medicinal Chemistry Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design Obesity: Current Treatment and Future Horizons
Mini-Reviews in Medicinal Chemistry Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal Chemistry Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Current Signal Transduction Therapy Pharmacological Strategies to Overcome HER2 Cross-Talk and Trastuzumab Resistance
Current Medicinal Chemistry Pegylated Interferons for the Treatment of Chronic Hepatitis B
Recent Patents on Anti-Infective Drug Discovery Current Molecularly Targeting Therapies in NSCLC and Melanoma
Anti-Cancer Agents in Medicinal Chemistry Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer
Current Cancer Drug Targets Metastatic Breast Cancer, Organotropism and Therapeutics: A Review
Current Cancer Drug Targets Suppression of Molecular Targets and Antiproliferative Effect of Citronellal on Triple-Negative Breast Cancer Cells
Current Molecular Pharmacology